Agenus traded at $1.96 this Friday July 1st, increasing $0.02 or 1.03 percent since the previous trading session. Looking back, over the last four weeks, Agenus gained 21.74 percent. Over the last 12 months, its price fell by 64.49 percent. Looking ahead, we forecast Agenus to be priced at 1.85 by the end of this quarter and at 1.70 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
1.96
Daily Change
1.03%
Yearly
-64.49%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Jiangsu Hengrui Me. 38.80 1.71 4.61% -42.01%
AbbVie 153.80 0.64 0.42% 33.54%
Agenus 1.96 0.02 1.03% -64.49%
Amgen 245.55 2.25 0.92% -1.27%
AstraZeneca 10,754.00 -46.00 -0.43% 22.50%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
ChemoCentryx 26.76 1.98 7.99% 103.03%
Celldex Therapeutics 22.70 -4.26 -15.80% -32.94%
CSL 269.23 0.17 0.06% -5.26%
Dynavax Technologies 12.96 0.37 2.94% 30.91%
Gilead Sciences 62.36 0.55 0.89% -10.01%
Genocea Biosciences 0.02 -0.002 -11.76% -99.33%
GlaxoSmithKline 1,785.60 20.00 1.13% 24.19%
Glaxosmithkline 43.75 0.22 0.51% 8.27%
Immunogen 4.61 0.11 2.44% -28.30%
Incyte Corp 77.67 1.70 2.24% -7.07%
J&J 179.52 2.01 1.13% 6.24%
Karyopharm Therapeutics 4.73 0.22 4.88% -55.00%
Eli Lilly 324.71 0.48 0.15% 38.79%
MacroGenics 3.05 0.10 3.39% -89.37%
Merck 165.70 4.70 2.92% 1.78%
Merck & Co 92.42 1.25 1.37% 17.58%
Novartis 80.33 -0.52 -0.64% -4.96%
Novavax 57.15 5.72 11.12% -73.69%
Northwest Biotherapeutics 0.64 0.01 0.81% -56.65%
Pfizer 52.31 -0.12 -0.23% 31.66%
Regeneron Pharmaceuticals 595.40 4.27 0.72% 2.01%
Rigel Pharmaceuticals 1.25 0.12 10.62% -71.66%
Sangamo BioSciences 4.28 0.14 3.38% -63.45%
Veracyte 21.10 1.20 6.03% -46.58%
Intrexon 1.41 0.07 5.22% -78.04%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Agenus
Agenus Inc. (Agenus) is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, neoantigen cancer vaccines (individualized and off-the shelf) platforms and adjuvants. Its anti-PD-1 antibody and first-generation and next generation anti-CTLA-4 antagonists are in clinical development. Its pipeline of pre-clinical assets, which include AGEN1777, an anti-TIGIT bispecific antibody and AGEN1327, an anti-TIGIT monospecific antibody. Its neoantigen vaccine platforms include its heat shock protein (HSP) based Prophage vaccine candidates and its synthetic, neoantigen vaccine candidates, AutoSynVax (ASV) and PhosphoSynVax (PSV). Its neoantigen vaccine platforms include individualized ASV and off-the-shelf PSV, which target antigens expressed across patients and tumors.